Latest & greatest articles for topiramate

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on topiramate or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on topiramate and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for topiramate

1. Comparative effectiveness of naltrexone, nalmefene, baclofen, acamprosate, and topiramate in the treatment of alcohol dependence or alcohol use disorders to reduce alcohol consumption: a systematic review and meta-analysis

Comparative effectiveness of naltrexone, nalmefene, baclofen, acamprosate, and topiramate in the treatment of alcohol dependence or alcohol use disorders to reduce alcohol consumption: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any

2017 PROSPERO

2. Trial of Amitriptyline, Topiramate, and Placebo for Pediatric Migraine. (PubMed)

Trial of Amitriptyline, Topiramate, and Placebo for Pediatric Migraine. Which medication, if any, to use to prevent the headache of pediatric migraine has not been established.We conducted a randomized, double-blind, placebo-controlled trial of amitriptyline (1 mg per kilogram of body weight per day), topiramate (2 mg per kilogram per day), and placebo in children and adolescents 8 to 17 years of age with migraine. Patients were randomly assigned in a 2:2:1 ratio to receive one (...) in the topiramate group, and 66 in the placebo group). The trial was concluded early for futility after a planned interim analysis. There were no significant between-group differences in the primary outcome, which occurred in 52% of the patients in the amitriptyline group, 55% of those in the topiramate group, and 61% of those in the placebo group (amitriptyline vs. placebo, P=0.26; topiramate vs. placebo, P=0.48; amitriptyline vs. topiramate, P=0.49). There were also no significant between-group differences

Full Text available with Trip Pro

2016 NEJM Controlled trial quality: predicted high

3. Is immediate-release topiramate an effective treatment for adult obesity?

Is immediate-release topiramate an effective treatment for adult obesity? Is immediate-release topiramate an effective treatment for adult obesity? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Is immediate-release topiramate an effective treatment for adult obesity? View/ Open Date 2014-12 Format Metadata Abstract Q (...) : Is immediate-release topiramate an effective treatment for adult obesity? Evidence-Based Answer: Yes. Topiramate (at daily doses of 64-400 mg) produces an average 5.34 kg of additional weight loss compared with placebo (95% confidence interval [CI], -6.12 to -4.56) in overweight to obese adults for periods of 16 to 60 weeks (strength of recommendation [SOR]: A, meta-analyses of randomized controlled trials [RCTs]). Topiramate increases the chances of losing 5% or more of aseline body weight (BBW

2015 Clinical Inquiries

4. Topiramate

Topiramate Top results for topiramate - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) ) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for topiramate The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you

2018 Trip Latest and Greatest

5. Flunarizine versus topiramate for chronic migraine prophylaxis: a randomized trial. (PubMed)

Flunarizine versus topiramate for chronic migraine prophylaxis: a randomized trial. Chronic migraine (CM) is a prevalent and devastating disorder with limited therapeutic options. This study explored the efficacy of 10 mg/d flunarizine for CM prophylaxis as compared with 50 mg/d topiramate.We conducted a prospective, randomized, open-label, blinded-endpoint trial. Patients with CM were randomized to flunarizine and topiramate treatment. The primary outcomes assessed were the reductions (...) in the total numbers of headache days and migraine days after 8 weeks of treatment. Secondary outcomes were reductions in the numbers of days of acute abortive medication intake and acute abortive medication tablets taken, and the 50% responder rate.Sixty-two subjects were randomized (n=31/group). Patients treated with flunarizine showed significant reductions in the numbers of total headache days (-4.9 vs -2.3, P=.012) and migraine days (-4.3 vs -1.4, P=.001) compared with those treated with topiramate

2016 Acta neurologica Scandinavica Controlled trial quality: uncertain

6. Topiramate for juvenile myoclonic epilepsy. (PubMed)

Topiramate for juvenile myoclonic epilepsy. Topiramate is a newer broad-spectrum antiepileptic drug (AED). Some studies have shown the benefits of topiramate in the treatment of juvenile myoclonic epilepsy (JME). However, there are no current systematic reviews to determine the efficacy and tolerability of topiramate in people with JME. This is an update of a Cochrane Review first published in 2015, and last updated in 2017.To evaluate the efficacy and tolerability of topiramate (...) topiramate versus placebo or other AED treatment for people with JME, with the outcomes of proportion of responders and proportion of participants experiencing adverse events (AEs).Two review authors independently screened the titles and abstracts of identified records, selected studies for inclusion, extracted data, cross-checked the data for accuracy and assessed the methodological quality. We performed no meta-analyses due to the limited available data.We included three studies with a total of 83

2019 Cochrane

7. Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate. (PubMed)

Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate. Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders (AUDs) is an emerging concept. Our objective was to explore the comparative effectiveness of drugs used in this indication.Systematic review with direct and network meta (...) -analysis of double-blind randomized controlled trials (RCTs) assessing the efficacy of nalmefene, naltrexone, acamprosate, baclofen or topiramate in non-abstinent adults diagnosed with alcohol dependence or AUDs. Two independent reviewers selected published and unpublished studies on Medline, the Cochrane Library, Embase, ClinicalTrials.gov, contacted pharmaceutical companies, the European Medicines Agency and the Food and Drug Administration, and extracted data.Thirty-two RCTs.A total of 6036

Full Text available with Trip Pro

2017 Addiction (Abingdon, England)

8. Efficacy and safety of topiramate on weight loss: a meta-analysis of randomized controlled trials

Efficacy and safety of topiramate on weight loss: a meta-analysis of randomized controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

9. Topiramate use early in pregnancy and the risk of oral clefts: A pregnancy cohort study

Topiramate use early in pregnancy and the risk of oral clefts: A pregnancy cohort study To assess the relative risk of oral clefts associated with maternal use of high and low doses of topiramate during the first trimester for epilepsy and nonepilepsy indications.This population-based study nested in the US 2000-2010 Medicaid Analytic eXtract included a cohort of 1,360,101 pregnant women with a live-born infant enrolled in Medicaid from 3 months before conception through 1 month after delivery (...) . Oral clefts were defined as the presence of a recorded diagnosis in claims during the first 90 days after birth. Women with a topiramate dispensing during the first trimester were compared with those without any dispensing and with an active reference group of women with a lamotrigine dispensing during the first trimester. Risk ratios (RRs) were estimated with generalized linear models with fine stratification on the propensity score of treatment to control for potential confounders. Stratified

2018 EvidenceUpdates

10. Efficacy of topiramate and valproate in chronic migraine. (PubMed)

Efficacy of topiramate and valproate in chronic migraine. The aim of this study was to compare the efficacy of sodium valproate and topiramate in treating chronic migraine.Forty-nine patients with chronic migraine were randomly assigned to 1 of 2 groups of treatment: 750 mg/day valproate or 75 mg/day topiramate. Efficacy variables were number of days with headache over a 30-day period and changes in Migraine Disability Assessment (MIDAS) scores at 3 months.At baseline the 2 groups had similar (...) numbers of days with headache and mean MIDAS scores. At the end of the treatment period, a significant reduction in 30-day headache frequency with respect to baseline (P < 0.00001) and a significant reduction in MIDAS scores (P < 0.00001) were recorded in both groups. There were no significant differences in beneficial effects between the 2 drugs.Valproate and topiramate seem to be able to manage successfully chronic migraine without substantial differences in efficacy and tolerability. This affords

2005 Clinical neuropharmacology Controlled trial quality: uncertain

11. Topiramate augmentation in patients with resistant major depressive disorder: a double-blind placebo-controlled clinical trial. (PubMed)

Topiramate augmentation in patients with resistant major depressive disorder: a double-blind placebo-controlled clinical trial. Despite evolution of new antidepressant treatment, clinicians still encounter challenges in the treatment of depressed patients. Looking for new medications that can potentiate the effects of current antidepressants seems to be necessary. Our objective is to survey the efficacy of topiramate augmentation in resistant major depressive disorder (MDD).This augmentation (...) trial was designed as an 8-week randomized, placebo-controlled, double-blind study. Fifty three patients with DSM-IV diagnosis of MDD who had failed to respond to at least 8 weeks of treatment with an adequate dose of one of the SSRIs (fluoxetine, citalopram or serteraline) were included in the study. Patients were randomized to receive a flexible dose of topiramate (100-200 mg/day) or placebo beside their current antidepressant medication for a period of eight weeks. Outcome measures were Hamilton

2011 Progress in neuro-psychopharmacology & biological psychiatry Controlled trial quality: uncertain

12. Cardiometabolic Disease Staging Predicts Effectiveness of Weight Loss Therapy to Prevent Type 2 Diabetes: Pooled Results From Phase III Clinical Trials Assessing Phentermine/Topiramate Extended Release

Cardiometabolic Disease Staging Predicts Effectiveness of Weight Loss Therapy to Prevent Type 2 Diabetes: Pooled Results From Phase III Clinical Trials Assessing Phentermine/Topiramate Extended Release To assess the ability of medication-assisted weight loss to prevent diabetes as a function of the baseline weighted Cardiometabolic Disease Staging (CMDS) score.We pooled data from 3,040 overweight and obese participants in three randomized controlled trials-CONQUER, EQUIP, and SEQUEL-assessing (...) efficacy and safety of phentermine/topiramate extended release (ER) for weight loss. In these double-blind phase III trials, overweight/obese adult patients were treated with a lifestyle intervention and randomly assigned to placebo versus once-daily oral phentermine/topiramate ER. The weighted CMDS score was calculated using baseline quantitative clinical data including waist circumference, blood glucose, blood pressure, and blood lipids. Incident diabetes was defined based on serial measures

Full Text available with Trip Pro

2017 EvidenceUpdates

13. Predictors of Topiramate Tolerability in Heavy Cannabis-Using Adolescents and Young Adults: A Secondary Analysis of a Randomized, Double-Blind, Placebo-Controlled Trial. (PubMed)

Predictors of Topiramate Tolerability in Heavy Cannabis-Using Adolescents and Young Adults: A Secondary Analysis of a Randomized, Double-Blind, Placebo-Controlled Trial. Cannabis is the most commonly abused illicit drug and accounts for the greatest number of adolescent substance abuse treatment admissions. Despite urgent need for effective interventions, the best available psychosocial treatment options yield only modest effects. Topiramate showed promise as an adjunctive pharmacotherapy (...) to a psychosocial intervention for cannabis misuse among adolescents and young adults in a recent clinical trial, but it was not well tolerated. This study investigated associations between clinical characteristics and side effects and dropout among adolescents and young adults randomized to topiramate.This study involved secondary data analysis of a randomized placebo-controlled trial of topiramate for treating cannabis misuse (ages, 15-24 years; 50% female). We explored the interaction effects of baseline

Full Text available with Trip Pro

2018 Journal of Clinical Psychopharmacology Controlled trial quality: predicted high

14. Topiramate for acute affective episodes in bipolar disorder in adults. (PubMed)

Topiramate for acute affective episodes in bipolar disorder in adults. Bipolar disorder is a common recurrent illness with high levels of chronicity. Previous trials have suggested that the anticonvulsant topiramate may be efficacious in bipolar disorder. This is an update of a previous Cochrane review (last published 2006) on the role of topiramate in bipolar disorder.To assess the effects of topiramate for acute mood episodes in bipolar disorder in adults compared to placebo, alternative (...) with authors and pharmaceutical companies.Randomised controlled trials comparing topiramate with placebo or with active agents in the treatment of acute mood episodes in adult male and female patients with bipolar disorder.Two review authors independently performed data extraction and methodological quality assessment. For analysis, we used odds ratio (OR) for binary efficacy outcomes and mean difference (MD) for continuously distributed outcomes.This review included six studies with a total of 1638 male

Full Text available with Trip Pro

2016 Cochrane

15. Randomised controlled trial: The combination of phentermine and topiramate is an effective adjunct to diet and lifestyle modification for weight loss and measures of comorbidity in overweight or obese adults with additional metabolic risk factors

Randomised controlled trial: The combination of phentermine and topiramate is an effective adjunct to diet and lifestyle modification for weight loss and measures of comorbidity in overweight or obese adults with additional metabolic risk factors The combination of phentermine and topiramate is an effective adjunct to diet and lifestyle modification for weight loss and measures of comorbidity in overweight or obese adults with additional metabolic risk factors | BMJ Evidence-Based Medicine We (...) of institutional accounts Username * Password * your user name or password? You are here The combination of phentermine and topiramate is an effective adjunct to diet and lifestyle modification for weight loss and measures of comorbidity in overweight or obese adults with additional metabolic risk factors Article Text Therapeutics Randomised controlled trial The combination of phentermine and topiramate is an effective adjunct to diet and lifestyle modification for weight loss and measures of comorbidity

2012 Evidence-Based Medicine

16. Topiramate + phentermine (Qsiva and other brands): an excessively dangerous appetite-suppressant combination

Topiramate + phentermine (Qsiva and other brands): an excessively dangerous appetite-suppressant combination Prescrire IN ENGLISH - Spotlight: Archive ''Topiramate + phentermine (Qsiva° and other brands): an excessively dangerous appetite-suppressant combination'', 1 March 2013 {1} {1} {1} | | > > > Topiramate + phentermine (Qsiva° and other brands): an excessively dangerous appetite-suppressant combination Spotlight: Archives Every month, the subjects in Prescrire’s Spotlight. 2013 :   (...) |   |  Spotlight Archives Topiramate + phentermine (Qsiva° and other brands): an excessively dangerous appetite-suppressant combination FEATURED REVIEW Overweight and obese patients must not be exposed to the topiramate + phentermine combination. No beneficial impact on clinical complications of obesity has been demonstrated. A portion of the weight lost is regained after treatment withdrawal. And numerous serious adverse effects have already been observed. Full review (4 pages) available

2014 Prescrire

17. Topiramate for the management of methamphetamine dependence: a pilot randomized, double-blind, placebo-controlled trial. (PubMed)

Topiramate for the management of methamphetamine dependence: a pilot randomized, double-blind, placebo-controlled trial. To date, no medication has been approved as an effective treatment for methamphetamine dependence. Topiramate has attracted considerable attention as a treatment for the dependence on alcohol and stimulants. Therefore, this study aimed to evaluate the effect of topiramate for methamphetamine dependence. This study was a double-blind, randomized, placebo-controlled trial (...) . In the present investigation, 62 methamphetamine-dependent adults were enrolled and randomized into two groups, and received topiramate or a placebo for 10 weeks in escalating doses from 50 mg/day to the target maintenance dose of 200 mg/day. Addiction severity index (ASI) and craving scores were registered every week. The Beck questionnaire was also given to each participant at baseline and every 2 weeks during the treatment. Urine samples were collected at baseline and every 2 weeks during the treatment

2016 Fundamental & clinical pharmacology Controlled trial quality: predicted high

18. Topiramate in Migraine Prevention: A 2016 Perspective. (PubMed)

Topiramate in Migraine Prevention: A 2016 Perspective. In evidence-based guidelines published in 2000, topiramate was a third-tier migraine preventive with no scientific evidence of efficacy; recommendation for its use reflected consensus opinion and clinical experience. Its neurostabilizing activity, coupled with its favorable weight profile, made topiramate an attractive alternative to other migraine preventives that caused weight gain. When guidelines for migraine prevention in episodic (...) migraine were published in 2012, topiramate was included as a first-line option based on double-blind, randomized controlled trials involving nearly 3000 patients. The scientific and clinical interest in topiramate has generated a large body of data from randomized controlled trials, meta-analyses, patient registries, cohort studies, and claims data analyses that have more fully characterized its role as a migraine preventive.This article will review the profile of topiramate that has emerged out

Full Text available with Trip Pro

2016 Headache

19. Topiramate add-on for drug-resistant partial epilepsy. (PubMed)

Topiramate add-on for drug-resistant partial epilepsy. The majority of people with epilepsy have a good prognosis and their seizures are controlled by a single antiepileptic drug. However, up to 20% of patients from population-based studies and up to 30% from clinical series (not population-based) develop drug-resistant epilepsy, especially those with partial onset seizures. In this review we summarise the current evidence regarding topiramate, an antiepileptic drug first marketed in 1996, when (...) used as an add-on treatment for drug-resistant partial epilepsy. This is an updated version of the original Cochrane review published in Issue 3, 1999.To evaluate the efficacy and safety of topiramate when used as an add-on treatment for people with drug-resistant partial epilepsy.We searched the Cochrane Epilepsy Group Specialised Register (June 2013); the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2013, Issue 5); MEDLINE (1946 to 2013); SCOPUS (1823 to 2013

2014 Cochrane

20. Adverse effects of galantamine, topiramate and cotrimoxazole

Adverse effects of galantamine, topiramate and cotrimoxazole Prescrire IN ENGLISH - Spotlight ''In the July issue of Prescrire International: adverse effects of galantamine, topiramate and cotrimoxazole'', 1 July 2015 {1} {1} {1} | | > > > In the July issue of Prescrire International: adverse effects of galantamine, topiramate and cotrimoxazole Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |  (...)  |   |   |  Spotlight In the July issue of Prescrire International: adverse effects of galantamine, topiramate and cotrimoxazole FREE DOWNLOAD All in one sample page: from serious skin reactions with Alzheimer's drug galantamine and visual field defects with topiramate to the potentially deadly effects of the antibiotic cotrimoxazole, either alone or when coadministrered with an ACE inhibitor or ARB. Sample page available for free download. Cotrimoxazole + an ACE inhibitor

2015 Prescrire